BioCentury | Dec 20, 2010
Company News

Inspire, Santen sales and marketing update

...Santen launched Diquas diquafosol tetrasodium ophthalmic solution 3% in Japan to treat dry eye. The launch...
...payment to Inspire under a 1998 deal that granted Santen rights to develop and commercialize diquafosol...
BioCentury | Aug 30, 2010
Company News

Inspire, Allergan deal

...dry eye treatment Restasis cyclosporine under a 2001 deal with Allergan for Restasis and Prolacria diquafosol...
BioCentury | Aug 16, 2010
Company News

Inspire, Santen sales and marketing update

...companies amended a 1998 deal under which Inspire granted Santen rights to develop and commercialize diquafosol...
...of a total of $6.3 million under the original deal, plus undisclosed royalties. Santen's Diquas diquafosol...
...ophthalmic solution 3% was approved in Japan in April to treat dry eye. Inspire's Prolacria diquafosol...
BioCentury | Jul 5, 2010
Finance

2Q approvals

...chemotherapy-induced neutropenia Inspire Pharmaceuticals Inc. (NASDAQ:ISPH)/ Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536) Japan approves Diquas diquafosol...
BioCentury | Apr 19, 2010
Finance

Regulatory milestones

...Ltd. (Tokyo:4536; Osaka:4536) said the Japanese Ministry of Health, Labor and Welfare (MHLW) approved Diquas diquafosol...
BioCentury | Apr 19, 2010
Clinical News

Diquas diquafosol tetrasodium ophthalmic solution 3% regulatory update

...Santen said the Japanese Ministry of Health, Labor and Welfare approved Diquas diquafosol tetrasodium ophthalmic solution...
...P2Y2 ligand in Japan by the end of the year. Santen has rights to the diquafosol...
...N.C. Allergan Inc. (NYSE:AGN), Irvine, Calif. Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536), Osaka, Product: Diquas diquafosol...
BioCentury | Apr 17, 2010
Company News

Japan approves Diquas for dry eye

...Co. Ltd. (Tokyo:4536; Osaka:4536) said the Japanese Ministry of Health, Labor and Welfare approved Diquas diquafosol...
...uridine 5'-triphosphate (UTP) natural P2Y2 ligand in Japan by year end. Santen has rights to diquafosol...
...other Asian countries from Inspire Pharmaceuticals Inc. (NASDAQ:ISPH), which is co-developing a 2% formulation of diquafosol...
BioCentury | Apr 5, 2010
Finance

1Q Approvals/1Q Setbacks

...the action will result in a Consent Decree. Inspire Pharmaceuticals Inc. (NASDAQ:ISPH)/Allergan Inc. (NYSE:AGN) Prolacria diquafosol...
BioCentury | Jan 25, 2010
Clinical News

Prolacria diquafosol tetrasodium: Phase III data

...Allergan Inc. (NYSE:AGN), Irvine, Calif. Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536), Osaka, Japan Product: Prolacria diquafosol...
BioCentury | Jan 25, 2010
Finance

Regulatory milestones

...Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) fell $1.07 (16%) to $5.54 on Thursday after reporting that Prolacria diquafosol...
Items per page:
1 - 10 of 76